Tralokinumab Effective in Phase 3 Atopic Dermatitis Studies Tralokinumab Effective in Phase 3 Atopic Dermatitis Studies

The investigational biologic agent for the treatment of moderate to severe atopic dermatitis hit all primary and secondary endpoints in three pivotal phase 3 clinical trials.Medscape Medical News

Source: Medscape Medical News Headlines - June 24, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news